Reports Q4 revenue $13.2M, consensus $11.74M. “We made solid progress on our key priorities in 2023,” said Neil F. McFarlane, President and Chief Executive Officer of Zevra. “As we look to 2024, our strategic priorities are clear; first, successfully launch OLPRUVA and ensure access for patients; second, prepare for the launch of arimoclomol; and third, advance the KP1077 development program in sleep disorders.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Options Volatility and Implied Earnings Moves Today, March 28, 2024
- Zevra Therapeutics’ KP1077 Shows Promise in Phase 2 Trial
- Zevra announces data from the Phase 2 clinical trial of KP1077or SDX for IH
- Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
- ZVRA Upcoming Earnings Report: What to Expect?
